{"entity":{"id":"nct04762069","kind":"trial","name":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","aka":[],"tldr":"A phase 2 trial of Berubicin in glioma & glioblastoma, run by CNS Pharmaceuticals, Inc., active and no longer recruiting.","summary":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme is a phase 2 interventional study registered as NCT04762069 by CNS Pharmaceuticals, Inc., with 252 participants enrolled, started 2021-05-18 and due to reach its primary completion in 2026-04-27. Interventions recorded: Berubicin and Lomustine.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04762069","url":"https://clinicaltrials.gov/study/NCT04762069"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04762069","phase":"2","setting":"A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy","sponsor":"CNS Pharmaceuticals, Inc.","enrolled":252,"outcomes":[]},"route":"/trials/nct04762069/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}